Salix Pharmaceuticals

Endo bids to acquire Salix for $11 billion

Thursday, March 12, 2015

Raleigh, N.C.-based Salix Pharmaceuticals has received an unsolicited proposal from Endo International, a global specialty healthcare company headquartered in Dublin, Ireland, to acquire all outstanding shares of common stock of the company for a combination of 1.4607 shares of Endo common stock and $45 cash per share of common stock. Based on the closing stock price of Endo on March 10, 2015, the transaction is valued at $175 per Salix share. 

[Read More]

Inversion rule change prompts AbbVie to halt Shire takeover

Thursday, October 16, 2014

In what could have been a major pharmaceutical acquisition and one of the biggest tax inversion deals, Chicago-based AbbVie has recommended its shareholders vote against its proposed $54 billion takeover of Shire, a Dublin-headquartered pharmaceutical company specializing in medications to treat attention deficit disorder and rare diseases

[Read More]

RedHill Biopharma, Salix Pharmaceuticals ink license agreement

Friday, February 28, 2014

Salix Pharmaceuticals, a North Carolina-based developer and marketer of prescription pharmaceutical products and medical devices, and RedHill Biopharma, an emerging Israeli biopharmaceutical company, have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.

[Read More]